CD47 and cancer: Combining the capability of P-NVs to target sites of surgical resection, the repolarization of TAMs towards an M1 phenotype, and the blockade of CD47-SIRPα interaction, we have demonstrated the hNVs can effectively promote macrophage phagocytosis of cancer cells, as well as boost antitumor T cell immunity within the TME.